These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 32979347)

  • 1. High prevalence of ROS1 gene rearrangement detected by FISH in EGFR and ALK negative lung adenocarcinoma.
    Xu Y; Chang H; Wu L; Zhang X; Zhang L; Zhang J; Li Y; Shen L; Zhu X; Zhou X; Bai Q
    Exp Mol Pathol; 2020 Dec; 117():104548. PubMed ID: 32979347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples.
    Zito Marino F; Rossi G; Cozzolino I; Montella M; Micheli M; Bogina G; Munari E; Brunelli M; Franco R
    J Clin Pathol; 2020 Feb; 73(2):96-101. PubMed ID: 31562206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
    Kim HR; Lim SM; Kim HJ; Hwang SK; Park JK; Shin E; Bae MK; Ou SH; Wang J; Jewell SS; Kang DR; Soo RA; Haack H; Kim JH; Shim HS; Cho BC
    Ann Oncol; 2013 Sep; 24(9):2364-70. PubMed ID: 23788756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical features of 54 cases of lung adenocarcinomas with c-ROS oncogene 1 fusion].
    Cao H; Zheng J; Zhao J; Guo XJ; Zhou JY; Ding W; Zhou JY
    Zhonghua Jie He He Hu Xi Za Zhi; 2020 Feb; 43(2):120-125. PubMed ID: 32062881
    [No Abstract]   [Full Text] [Related]  

  • 5. PD-L1 expression in ROS1-rearranged non-small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1.
    Lee J; Park CK; Yoon HK; Sa YJ; Woo IS; Kim HR; Kim SY; Kim TJ
    Thorac Cancer; 2019 Jan; 10(1):103-110. PubMed ID: 30475455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CT features and disease spread patterns in ROS1-rearranged lung adenocarcinomas: comparison with those of EGFR-mutant or ALK-rearranged lung adenocarcinomas.
    Woo JH; Kim TJ; Kim TS; Han J
    Sci Rep; 2020 Oct; 10(1):16251. PubMed ID: 33005033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
    Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A
    Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution of lung adenocarcinoma from preneoplasia to invasive adenocarcinoma.
    Zhu J; Wang W; Xiong Y; Xu S; Chen J; Wen M; Zhao Y; Lei J; Jiang T
    Cancer Med; 2023 Mar; 12(5):5545-5557. PubMed ID: 36325966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non-small-cell Lung Cancer: Implications of FISH-positive Patterns.
    Clavé S; Rodon N; Pijuan L; Díaz O; Lorenzo M; Rocha P; Taus Á; Blanco R; Bosch-Barrera J; Reguart N; de la Torre N; Oliveras G; Espinet B; Bellosillo B; Puig X; Arriola E; Salido M
    Clin Lung Cancer; 2019 Jul; 20(4):e421-e429. PubMed ID: 30898567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a Dual ALK/ROS1 Fluorescent In Situ Hybridization Test in Non-Small-cell Lung Cancer.
    Ginestet F; Lambros L; Le Flahec G; Marcorelles P; Uguen A
    Clin Lung Cancer; 2018 Sep; 19(5):e647-e653. PubMed ID: 29801706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coexistent genetic alterations involving ALK, RET, ROS1 or MET in 15 cases of lung adenocarcinoma.
    Tang Z; Zhang J; Lu X; Wang W; Chen H; Robinson MK; Cheng J; Tang G; Medeiros LJ
    Mod Pathol; 2018 Feb; 31(2):307-312. PubMed ID: 28914263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testing for ROS1, ALK, MET, and HER2 rearrangements and amplifications in a large series of biliary tract adenocarcinomas.
    Augustin J; Gabignon C; Scriva A; Menu L; Calmel C; Scatton O; Paye F; Fléjou JF; Praz F; Cervera P; Wendum D
    Virchows Arch; 2020 Jul; 477(1):33-45. PubMed ID: 32447492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.
    Nozaki Y; Yamamoto H; Iwasaki T; Sato M; Jiromaru R; Hongo T; Yasumatsu R; Oda Y
    Hum Pathol; 2020 Dec; 106():82-92. PubMed ID: 32980422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma.
    Kim MH; Shim HS; Kang DR; Jung JY; Lee CY; Kim DJ; Lee JG; Bae MK; Kim HR; Lim SM; Kim EY; Park JS; Chung KY; Kim HJ; Kim JH; Cho BC
    Lung Cancer; 2014 Mar; 83(3):389-95. PubMed ID: 24462463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer.
    Lim SM; Chang H; Cha YJ; Liang S; Tai YC; Li G; Pestova E; Policht F; Perez T; Soo RA; Park WY; Kim HR; Shim HS; Cho BC
    Lung Cancer; 2017 Sep; 111():79-83. PubMed ID: 28838404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients.
    Schluckebier L; Caetano R; Garay OU; Montenegro GT; Custodio M; Aran V; Gil Ferreira C
    BMC Cancer; 2020 Sep; 20(1):875. PubMed ID: 32928143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR mutations and ROS1 and ALK rearrangements in a large series of non-small cell lung cancer in South India.
    Tarigopula A; Ramasubban G; Chandrashekar V; Govindasami P; Chandran C
    Cancer Rep (Hoboken); 2020 Dec; 3(6):e1288. PubMed ID: 32881404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.
    Chen YF; Hsieh MS; Wu SG; Chang YL; Yu CJ; Yang JC; Yang PC; Shih JY
    J Thorac Oncol; 2016 Jul; 11(7):1140-52. PubMed ID: 27094798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients.
    Bozzetti C; Nizzoli R; Tiseo M; Squadrilli A; Lagrasta C; Buti S; Gasparro D; Zanoni D; Majori M; De Filippo M; Mazzoni F; Maddau C; Naldi N; Sammarelli G; Frati C; Pinto C; Ardizzoni A
    Diagn Cytopathol; 2015 Nov; 43(11):941-6. PubMed ID: 26152804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ligation-dependent RT-PCR: a new specific and low-cost technique to detect ALK, ROS, and RET rearrangements in lung adenocarcinoma.
    Piton N; Ruminy P; Gravet C; Marchand V; Colasse É; Lamy A; Naoures Mear CL; Bibeau F; Marguet F; Guisier F; Salaün M; Thiberville L; Jardin F; Sabourin JC
    Lab Invest; 2018 Mar; 98(3):371-379. PubMed ID: 29251734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.